Abcam

Anti-BRAF (mutated V600E) antibody [VE1]

#ab228461 · western blot

25
Citing papers
257
Combined citations
Supplier page Find this product

Research areas

Thyroid Cancer Diagnosis and Treatment10Genetic factors in colorectal cancer3Single-cell and spatial transcriptomics3Thyroid Disorders and Treatments3Cutaneous Melanoma Detection and Management3Head and Neck Anomalies2Cancer Cells and Metastasis2Cancer-related Molecular Pathways2

Papers citing this product

1
BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation
Oncogene·2020·43 cit.·DOI
2
Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks
Nature Communications·2024·42 cit.·DOI
3
GABA Regulates Electrical Activity and Tumor Initiation in Melanoma
Cancer Discovery·2023·40 cit.·DOI
4
Lipid droplets are a metabolic vulnerability in melanoma
Nature Communications·2023·37 cit.·DOI
5
Immunoprofile of adenosquamous carcinoma in gastric cancer
Journal of the Chinese Medical Association·2023·20 cit.·DOI
6
Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
Journal of Clinical Medicine·2020·17 cit.·DOI
7
A New Indicator to Differentiate Thyroid Follicular Inclusions in Cervical Lymph Nodes from Patients with Thyroid Cancer
International Journal of Molecular Sciences·2022·14 cit.·DOI
8
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma
Endocrine Pathology·2025·11 cit.·DOI
9
Co-dependent regulation of p-BRAF and potassium channel KCNMA1 levels drives glioma progression
Cellular and Molecular Life Sciences·2023·7 cit.·DOI
10
BRAFV600E Expression Is Homogenous and Associated with Nonrecurrent Disease and Better Survival in Primary Melanoma
Dermatology·2023·4 cit.·DOI
Anti-BRAF (mutated V600E) antibody [VE1] — Evidence — PubIndex